Literature DB >> 9741865

A design alternative for two-stage, phase II, multicenter cancer clinical trials.

J E Herndon1.   

Abstract

Data are reviewed upon completion of patient accrual to the first stage of a two-stage phase II cancer clinical trial and prior to initiating accrual on the second stage. Often accrual must be suspended while the data from the first stage are collected and evaluated. In an effort to maintain patient accrual momentum and avoid the logistical problems of suspending and reactivating a multicenter study, an alternative approach to conducting two-stage phase II studies, which allows patient accrual to continue while the results of the first stage are reviewed, is proposed. The properties of the proposed design are examined.

Entities:  

Mesh:

Year:  1998        PMID: 9741865     DOI: 10.1016/s0197-2456(98)00012-9

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  9 in total

Review 1.  Statistics in clinical trials.

Authors:  Stephanie J Green; Donna K Pauler
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

Review 2.  Modelling and simulation in the development and use of anti-cancer agents: an underused tool?

Authors:  Ferdinand Rombout; Leon Aarons; Mats Karlsson; Anthony Man; France Mentré; Peter Nygren; Amy Racine; Hans Schaefer; Jean-Louis Steimer; Iñaki Troconiz; Achiel van Peer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-12       Impact factor: 2.745

3.  A predictive probability design for phase II cancer clinical trials.

Authors:  J Jack Lee; Diane D Liu
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

4.  Suspension of accrual in phase II cancer clinical trials.

Authors:  Yimei Li; Rosemarie Mick; Daniel F Heitjan
Journal:  Clin Trials       Date:  2015-01-07       Impact factor: 2.486

Review 5.  Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.

Authors:  Sin-Ho Jung
Journal:  Contemp Clin Trials       Date:  2015-03-03       Impact factor: 2.226

6.  Advances in Statistical Approaches Oncology Drug Development.

Authors:  Anastasia Ivanova; Gary L Rosner; Olga Marchenko; Tom Parke; Inna Perevozskaya; Yanping Wang
Journal:  Ther Innov Regul Sci       Date:  2014-01       Impact factor: 1.778

7.  A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials.

Authors:  Yimei Li; Rosemarie Mick; Daniel F Heitjan
Journal:  Clin Trials       Date:  2012-04-20       Impact factor: 2.486

8.  Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint.

Authors:  Lili Zhao; Jeremy M G Taylor; Scott M Schuetze
Journal:  Stat Med       Date:  2012-02-23       Impact factor: 2.373

9.  Design of Phase II cancer trials evaluating survival probabilities.

Authors:  L Douglas Case; Timothy M Morgan
Journal:  BMC Med Res Methodol       Date:  2003-04-03       Impact factor: 4.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.